US-based Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Germnay-based Bayer AG, announced on Thursday that it has named Gustavo Pesquin as its new chief executive officer (CEO) effective 11 March 2023.
Pesquin has served as chief commercial officer at Amneal Pharmaceuticals, Inc. He has over 10 years of experience at Sanofi, where he served in leadership roles of increasing responsibility, including North America head for General Medicines and global head of the Diabetes and Cardiovascular Franchise. He has held the position of regional head, general manager, sales head and strategy head roles at Abbott and Pfizer; brand management roles at Procter & Gamble; and consultant roles with Boston Consulting Group.
Pesquin holds an MBA with a concentration in Management and Strategy, Finance and Accounting from Kellogg School of Management at Northwestern University and a bachelor's degree in Public and Business Administration from Universidad Nacional de Cuyo in Argentina.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies